Last reviewed · How we verify
Tafluprost 0.0015%
Tafluprost 0.0015%, marketed by FinnMedi Oy, is a glaucoma treatment with a key composition patent expiring in 2028. The drug's market position is bolstered by its patented mechanism, which provides a competitive edge until the patent expiry. The primary risk is the potential increase in competition post-2028, as generic versions may enter the market.
At a glance
| Generic name | Tafluprost 0.0015% |
|---|---|
| Also known as | Taflotan®, Taflotan sine®, Saflutan®, Saflutan Conserveermiddelvrij® |
| Sponsor | FinnMedi Oy |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
- Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution) (NA)
- Tafluprost Preservative Free Switch Study (PHASE4)
- Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients
- Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002) (PHASE3)
- Efficacy of Tafluprost as an Adjunct to Medical Therapy for Residual Glaucoma After Trabeculectomy (NA)
- The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafluprost 0.0015% CI brief — competitive landscape report
- Tafluprost 0.0015% updates RSS · CI watch RSS
- FinnMedi Oy portfolio CI